Oxford Immunotec Global Stock Price, News & Analysis (NASDAQ:OXFD)

$12.13 +0.17 (+1.42 %)
(As of 02/25/2018 02:40 AM ET)
Previous Close$12.13
Today's Range$11.80 - $12.21
52-Week Range$10.00 - $19.51
Volume59,865 shs
Average Volume148,531 shs
Market Capitalization$306.83 million
P/E Ratio-6.00
Dividend YieldN/A
Beta-0.3

About Oxford Immunotec Global (NASDAQ:OXFD)

Oxford Immunotec Global logoOxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company's product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. Its T-SPOT.TB test is used to test for tuberculosis (TB), infection and leverages its T-SPOT technology platform, which allows it to measure the response of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease. Its T-SPOT. CMV and T-SPOT. PRT tests are part of its product line focused on the transplantation market.

Receive OXFD News and Ratings via Email

Sign-up to receive the latest news and ratings for OXFD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Diagnostic & Testing Equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OXFD
CUSIPN/A
Phone44-0-12-3544-2780

Debt

Debt-to-Equity Ratio0.38%
Current Ratio4.72%
Quick Ratio4.30%

Price-To-Earnings

Trailing P/E Ratio-6.00495049504951
Forward P/E Ratio-5.62
P/E GrowthN/A

Sales & Book Value

Annual Sales$86.08 million
Price / Sales3.62
Cash FlowN/A
Price / CashN/A
Book Value$3.23 per share
Price / Book3.76

Profitability

Trailing EPS($2.02)
Net Income$-22,340,000.00
Net Margins-45.74%
Return on Equity-38.42%
Return on Assets-21.18%

Miscellaneous

Employees432
Outstanding Shares25,660,000

Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions

What is Oxford Immunotec Global's stock symbol?

Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."

How were Oxford Immunotec Global's earnings last quarter?

Oxford Immunotec Global PLC (NASDAQ:OXFD) announced its quarterly earnings data on Tuesday, August, 2nd. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.04. The business earned $19.20 million during the quarter, compared to the consensus estimate of $18.10 million. Oxford Immunotec Global had a negative return on equity of 38.42% and a negative net margin of 45.74%. Oxford Immunotec Global's revenue for the quarter was up 34.3% on a year-over-year basis. During the same period in the prior year, the company earned ($0.33) EPS. View Oxford Immunotec Global's Earnings History.

When will Oxford Immunotec Global make its next earnings announcement?

Oxford Immunotec Global is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Oxford Immunotec Global.

Where is Oxford Immunotec Global's stock going? Where will Oxford Immunotec Global's stock price be in 2018?

4 analysts have issued 12 month price objectives for Oxford Immunotec Global's shares. Their predictions range from $15.00 to $21.00. On average, they expect Oxford Immunotec Global's stock price to reach $18.75 in the next twelve months. View Analyst Ratings for Oxford Immunotec Global.

What are Wall Street analysts saying about Oxford Immunotec Global stock?

Here are some recent quotes from research analysts about Oxford Immunotec Global stock:

  • 1. According to Zacks Investment Research, "Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company's first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. " (1/23/2018)
  • 2. BTIG Research analysts commented, "This evening bluebird provided a 1Q update via press release (no conference call, as usual). Following an April meeting with the EMA, BLUE updated its EU regulatory strategy noting that it anticipates filing for conditional approval in non-B0/B0 patients on the basis of the ongoing Northstar and HGB-205 studies, plus data available from the ongoing Northstar-2 at the time of filing. Amount of follow up needed from Northstar and HGB-205 is TBD (data dependent and discussions with the EMA are ongoing). On the catalyst front, previously announced timelines are intact, and 2017 is looking to be a busy year for bluebird. Overall, we remain encouraged with the company’s continued progress across multiple clinical programs involving its potentially transformative gene therapy and CAR-T platforms. Maintain OW." (5/4/2017)

Who are some of Oxford Immunotec Global's key competitors?

Who are Oxford Immunotec Global's key executives?

Oxford Immunotec Global's management team includes the folowing people:

  • Richard A. Sandberg, Independent Chairman of the Board (Age 74)
  • Peter James Wrighton-Smith Ph.D., Chief Executive Officer, Director (Age 42)
  • Richard M. Altieri, Chief Financial Officer (Age 57)
  • Stefan C. Linn, Chief Operating Officer (Age 51)
  • Peter Edwardson Ph.D., Senior Vice President & Head of Blood Screening (Age 52)
  • Elizabeth M. Keiley, Vice President, General Counsel (Age 51)
  • Richard J. Wenstrup M.D., Chief Medical Officer (Age 64)
  • Ronald A. Andrews Jr., Director (Age 57)
  • Patrick J. Balthrop Sr., Director (Age 60)
  • Patricia Randall, Director (Age 66)

Who owns Oxford Immunotec Global stock?

Oxford Immunotec Global's stock is owned by a number of of institutional and retail investors. Top institutional investors include Redmile Group LLC (9.04%), Consonance Capital Management LP (4.36%), BlackRock Inc. (4.24%), Grandeur Peak Global Advisors LLC (3.05%), Cortina Asset Management LLC (2.56%) and Endurant Capital Management LP (2.22%). Company insiders that own Oxford Immunotec Global stock include Elizabeth M Keiley, Jeff R Schroeder, Peter Edwardson, Peter Wrighton-Smith and Richard A Sandberg. View Institutional Ownership Trends for Oxford Immunotec Global.

Who sold Oxford Immunotec Global stock? Who is selling Oxford Immunotec Global stock?

Oxford Immunotec Global's stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Endurant Capital Management LP, Renaissance Technologies LLC, Spark Investment Management LLC, C WorldWide Group Holding A S, Flinton Capital Management LLC, Two Sigma Advisers LP and Wasatch Advisors Inc.. Company insiders that have sold Oxford Immunotec Global company stock in the last year include Elizabeth M Keiley, Jeff R Schroeder, Peter Edwardson, Peter Wrighton-Smith and Richard A Sandberg. View Insider Buying and Selling for Oxford Immunotec Global.

Who bought Oxford Immunotec Global stock? Who is buying Oxford Immunotec Global stock?

Oxford Immunotec Global's stock was purchased by a variety of institutional investors in the last quarter, including Consonance Capital Management LP, Redmile Group LLC, Millennium Management LLC, Kennedy Capital Management Inc., Cortina Asset Management LLC, Grandeur Peak Global Advisors LLC, BlackRock Inc. and Penn Capital Management Co. Inc.. View Insider Buying and Selling for Oxford Immunotec Global.

How do I buy Oxford Immunotec Global stock?

Shares of Oxford Immunotec Global can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oxford Immunotec Global's stock price today?

One share of Oxford Immunotec Global stock can currently be purchased for approximately $12.13.

How big of a company is Oxford Immunotec Global?

Oxford Immunotec Global has a market capitalization of $306.83 million and generates $86.08 million in revenue each year. The company earns $-22,340,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. Oxford Immunotec Global employs 432 workers across the globe.

How can I contact Oxford Immunotec Global?

Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]


MarketBeat Community Rating for Oxford Immunotec Global (OXFD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  236
MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Oxford Immunotec Global (NASDAQ:OXFD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.75$18.75$19.75$21.33
Price Target Upside: 62.90% upside62.90% upside49.39% upside32.26% upside

Oxford Immunotec Global (NASDAQ:OXFD) Consensus Price Target History

Price Target History for Oxford Immunotec Global (NASDAQ:OXFD)

Oxford Immunotec Global (NASDAQ:OXFD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/22/2018CowenReiterated RatingBuy$15.00HighView Rating Details
12/18/2017BTIG ResearchSet Price TargetBuy$21.00MediumView Rating Details
11/1/2017Robert W. BairdReiterated RatingBuy$20.00N/AView Rating Details
10/31/2017Piper Jaffray CompaniesLower Price TargetOverweight$26.00 -> $19.00N/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Oxford Immunotec Global (NASDAQ:OXFD) Earnings History and Estimates Chart

Earnings by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Oxford Immunotec Global (NASDAQ OXFD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018($0.36)N/AView Earnings Details
10/31/2017Q3 2017($0.26)($0.24)$30.11 million$30.43 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.32)($0.32)$25.05 million$26.10 millionViewListenView Earnings Details
5/2/20173/31/2017($0.35)($0.36)$21.17 million$21.51 millionViewListenView Earnings Details
3/1/201712/31/2016($0.39)($0.22)$23.06 million$23.71 millionViewListenView Earnings Details
11/1/2016Q316($0.33)($0.18)$24.79 million$26.10 millionViewN/AView Earnings Details
8/2/2016Q216($0.33)($0.29)$18.10 million$19.20 millionViewN/AView Earnings Details
5/3/2016Q116($0.32)($0.32)$16.96 million$17.10 millionViewN/AView Earnings Details
3/1/2016Q415($0.28)($0.29)$16.34 million$16.00 millionViewN/AView Earnings Details
11/3/2015Q315($0.25)($0.20)$17.31 million$17.90 millionViewN/AView Earnings Details
8/4/2015Q215($0.34)($0.33)$14.04 million$14.30 millionViewN/AView Earnings Details
5/5/2015Q115($0.33)($0.31)$13.35 million$13.80 millionViewN/AView Earnings Details
3/3/2015Q414($0.44)($0.39)$11.93 million$12.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.38)($0.35)$12.85 million$13.30 millionViewN/AView Earnings Details
8/5/2014Q214($0.20)($0.36)$11.39 million$11.80 millionViewN/AView Earnings Details
5/6/2014Q114($0.18)($0.18)$11.64 million$12.30 millionViewN/AView Earnings Details
3/4/2014Q413($0.19)($0.38)$9.28 million$10.20 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Oxford Immunotec Global (NASDAQ:OXFD) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.16 EPS
Next Year EPS Consensus Estimate: $-1.06 EPS

Dividends

Dividend History for Oxford Immunotec Global (NASDAQ:OXFD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Oxford Immunotec Global (NASDAQ OXFD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.11%
Institutional Ownership Percentage: 88.00%
Insider Trades by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)
Institutional Ownership by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Oxford Immunotec Global (NASDAQ OXFD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/16/2018Richard A SandbergDirectorSell3,000$12.01$36,030.00View SEC Filing  
11/1/2017Richard A SandbergDirectorSell3,000$13.35$40,050.0017,778View SEC Filing  
10/2/2017Peter Wrighton-SmithCEOSell55,000$16.78$922,900.00View SEC Filing  
9/1/2017Richard A SandbergDirectorSell3,000$15.82$47,460.0018,000View SEC Filing  
8/15/2017Peter EdwardsonCOOSell9,739$16.14$157,187.4692,905View SEC Filing  
8/7/2017Peter EdwardsonCOOSell22,371$17.70$395,966.70102,644View SEC Filing  
7/6/2017Peter Wrighton-SmithCEOSell27,168$15.94$433,057.92488,836View SEC Filing  
7/5/2017Peter Wrighton-SmithCEOSell32,832$16.58$544,354.56478,106View SEC Filing  
6/28/2017Peter Wrighton-SmithCEOSell30,000$16.06$481,800.00491,668View SEC Filing  
6/15/2017Elizabeth M KeileyVPSell4,085$15.01$61,315.8525,393View SEC Filing  
5/15/2017Peter EdwardsonCOOSell10,000$14.66$146,600.00125,015View SEC Filing  
5/10/2017Richard A SandbergDirectorSell3,000$14.40$43,200.0020,174View SEC Filing  
5/9/2017Jeff R SchroederInsiderSell40,000$14.14$565,600.00149,544View SEC Filing  
4/3/2017Peter Wrighton-SmithCEOSell30,000$15.43$462,900.00491,668View SEC Filing  
4/3/2017Richard A SandbergDirectorSell3,000$15.47$46,410.0017,174View SEC Filing  
3/20/2017Elizabeth M KeileyVPSell3,000$16.05$48,150.0025,429View SEC Filing  
2/6/2017Peter Wrighton-SmithCEOSell25,000$13.36$334,000.00463,495View SEC Filing  
12/16/2016Peter Wrighton-SmithCEOSell7,052$15.07$106,273.64450,366View SEC Filing  
12/5/2016Peter Wrighton-SmithCEOSell1,140$15.00$17,100.00444,454View SEC Filing  
12/2/2016Peter Wrighton-SmithCEOSell61,808$15.00$927,120.00504,122View SEC Filing  
11/8/2016Richard A SandbergDirectorSell12,000$14.17$170,040.0031,774View SEC Filing  
11/18/2015Richard A. SandbergDirectorSell5,000$13.48$67,400.0032,174View SEC Filing  
11/17/2015Richard A. SandbergDirectorSell5,000$13.00$65,000.0037,174View SEC Filing  
6/16/2015Lifesciences I L.P. ClarusMajor ShareholderSell41,230$14.30$589,589.00View SEC Filing  
6/15/2015Lifesciences I L.P. ClarusMajor ShareholderSell1,529$14.27$21,818.83View SEC Filing  
6/12/2015Lifesciences I L.P. ClarusMajor ShareholderSell31,598$14.27$450,903.46View SEC Filing  
6/10/2015Lifesciences I L.P. ClarusMajor ShareholderSell24,649$14.28$351,987.72View SEC Filing  
6/9/2015Lifesciences I L.P. ClarusMajor ShareholderSell13,000$14.26$185,380.00View SEC Filing  
6/8/2015Lifesciences I L.P. ClarusMajor ShareholderSell2,662$14.25$37,933.50View SEC Filing  
6/3/2015Lifesciences I L.P. ClarusMajor ShareholderSell36,474$14.29$521,213.46View SEC Filing  
6/1/2015Richard A SandbergDirectorSell3,000$14.14$42,420.00View SEC Filing  
3/23/2015Lifesciences I L.P. ClarusMajor ShareholderSell53,415$14.49$773,983.35View SEC Filing  
3/19/2015Lifesciences I L.P. ClarusMajor ShareholderSell154,319$14.65$2,260,773.35View SEC Filing  
1/14/2015Richard A SandbergDirectorSell3,000$14.00$42,000.00View SEC Filing  
12/5/2014Patricia RandallDirectorSell5,000$12.06$60,300.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Oxford Immunotec Global (NASDAQ OXFD) News Headlines

Source:
DateHeadline
Oxford Immunotec Global (OXFD) Upgraded to Hold by BidaskClubOxford Immunotec Global (OXFD) Upgraded to Hold by BidaskClub
www.americanbankingnews.com - February 24 at 10:22 PM
-$0.36 Earnings Per Share Expected for Oxford Immunotec Global PLC (OXFD) This Quarter-$0.36 Earnings Per Share Expected for Oxford Immunotec Global PLC (OXFD) This Quarter
www.americanbankingnews.com - February 24 at 8:06 AM
Oxford Immunotec Global (OXFD) Scheduled to Post Quarterly Earnings on TuesdayOxford Immunotec Global (OXFD) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 20 at 4:46 AM
Oxford Immunotec Global PLC (OXFD) Given Average Recommendation of "Hold" by AnalystsOxford Immunotec Global PLC (OXFD) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 19 at 1:46 AM
Insider Selling: Oxford Immunotec Global PLC (OXFD) Director Sells 3,000 Shares of StockInsider Selling: Oxford Immunotec Global PLC (OXFD) Director Sells 3,000 Shares of Stock
www.americanbankingnews.com - February 16 at 10:20 PM
Oxford Immunotec Schedules Fourth Quarter and Full Year 2017 Earnings Release and Conference Call for February 27, 2018Oxford Immunotec Schedules Fourth Quarter and Full Year 2017 Earnings Release and Conference Call for February 27, 2018
finance.yahoo.com - February 13 at 4:28 PM
BRIEF-James Flynn Reports 5.1 Pct Passive Stake In Oxford Immunotec Global Plc As Of Jan 22BRIEF-James Flynn Reports 5.1 Pct Passive Stake In Oxford Immunotec Global Plc As Of Jan 22
www.reuters.com - February 2 at 9:07 AM
Oxford Immunotec Global PLC (OXFD) Receives Average Recommendation of "Hold" from BrokeragesOxford Immunotec Global PLC (OXFD) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 25 at 1:30 AM
Oxford Immunotec Announces Preliminary Revenue for Fourth Quarter and Full Year 2017Oxford Immunotec Announces Preliminary Revenue for Fourth Quarter and Full Year 2017
finance.yahoo.com - January 8 at 9:17 AM
$25.88 Million in Sales Expected for Oxford Immunotec Global PLC (OXFD) This Quarter$25.88 Million in Sales Expected for Oxford Immunotec Global PLC (OXFD) This Quarter
www.americanbankingnews.com - January 6 at 4:14 AM
-$0.36 EPS Expected for Oxford Immunotec Global PLC (OXFD) This Quarter-$0.36 EPS Expected for Oxford Immunotec Global PLC (OXFD) This Quarter
www.americanbankingnews.com - January 4 at 1:30 PM
Oxford Immunotec to Present at the 36th Annual J.P. Morgan Healthcare ConferenceOxford Immunotec to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 9:30 AM
Oxford Immunotec Global Plc breached its 50 day moving average in a Bearish Manner : OXFD-US : January 1, 2018Oxford Immunotec Global Plc breached its 50 day moving average in a Bearish Manner : OXFD-US : January 1, 2018
finance.yahoo.com - January 1 at 10:03 AM
Oxford Immunotec Global PLC (OXFD) Given Consensus Rating of "Hold" by AnalystsOxford Immunotec Global PLC (OXFD) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - December 31 at 1:58 AM
Oxford Immunotec Global Plc is trading above its 50 day moving average : OXFD-US : December 20, 2017Oxford Immunotec Global Plc is trading above its 50 day moving average : OXFD-US : December 20, 2017
finance.yahoo.com - December 20 at 10:16 AM
Oxford Immunotec Global (OXFD) PT Set at $21.00 by BTIG ResearchOxford Immunotec Global (OXFD) PT Set at $21.00 by BTIG Research
www.americanbankingnews.com - December 19 at 10:22 AM
BRIEF-Oxford Immunotec And Qiagen Reached A Settlement In LawsuitBRIEF-Oxford Immunotec And Qiagen Reached A Settlement In Lawsuit
www.reuters.com - December 16 at 4:40 PM
Oxford Immunotec Global (OXFD) Lifted to Hold at BidaskClubOxford Immunotec Global (OXFD) Lifted to Hold at BidaskClub
www.americanbankingnews.com - December 16 at 12:02 PM
Oxford Immunotec and QIAGEN N.V. Settle Patent Infringement LawsuitOxford Immunotec and QIAGEN N.V. Settle Patent Infringement Lawsuit
finance.yahoo.com - December 15 at 5:00 PM
QIAGEN and Oxford Immunotec Settle Patent Infringement LawsuitQIAGEN and Oxford Immunotec Settle Patent Infringement Lawsuit
finance.yahoo.com - December 15 at 5:00 PM
BidaskClub Lowers Oxford Immunotec Global (OXFD) to SellBidaskClub Lowers Oxford Immunotec Global (OXFD) to Sell
www.americanbankingnews.com - December 9 at 9:30 AM
Oxford Immunotec Global PLC (OXFD) Receives Average Recommendation of "Hold" from AnalystsOxford Immunotec Global PLC (OXFD) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 6 at 1:46 AM
Oxford Immunotec Global PLC (OXFD) Expected to Post Earnings of -$0.33 Per ShareOxford Immunotec Global PLC (OXFD) Expected to Post Earnings of -$0.33 Per Share
www.americanbankingnews.com - November 30 at 9:32 PM
Oxford Immunotec: Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare ConferenceOxford Immunotec: Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare Conference
www.finanznachrichten.de - November 22 at 6:30 AM
BRIEF-Oxford Immunotec Global Plc says unit entered into a 2nd amendment to purchase agreement with Mabtech ABBRIEF-Oxford Immunotec Global Plc says unit entered into a 2nd amendment to purchase agreement with Mabtech AB
www.reuters.com - November 22 at 6:30 AM
Zacks: Brokerages Anticipate Oxford Immunotec Global PLC (OXFD) Will Announce Quarterly Sales of $25.88 MillionZacks: Brokerages Anticipate Oxford Immunotec Global PLC (OXFD) Will Announce Quarterly Sales of $25.88 Million
www.americanbankingnews.com - November 14 at 9:50 AM
Zacks: Analysts Expect Oxford Immunotec Global PLC (OXFD) Will Announce Earnings of -$0.34 Per ShareZacks: Analysts Expect Oxford Immunotec Global PLC (OXFD) Will Announce Earnings of -$0.34 Per Share
www.americanbankingnews.com - November 12 at 9:30 AM
Oxford Immunotec Global PLC (OXFD) Given Average Recommendation of "Hold" by BrokeragesOxford Immunotec Global PLC (OXFD) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 11 at 1:46 AM
Oxford Immunotec to Present at the Jefferies 2017 London Healthcare ConferenceOxford Immunotec to Present at the Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 10 at 9:33 AM
ETFs with exposure to Oxford Immunotec Global Plc : November 6, 2017ETFs with exposure to Oxford Immunotec Global Plc : November 6, 2017
finance.yahoo.com - November 7 at 8:20 AM
Oxford Immunotec Global PLC (OXFD) Downgraded by Zacks Investment Research to SellOxford Immunotec Global PLC (OXFD) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - November 4 at 10:13 AM
Oxford Immunotec Global Plc :OXFD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Oxford Immunotec Global Plc :OXFD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 4 at 8:39 AM
Oxford Immunotec Global Plc :OXFD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Oxford Immunotec Global Plc :OXFD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 4 at 8:39 AM
Oxford Immunotec Global PLC (OXFD) Director Richard A. Sandberg Sells 3,000 SharesOxford Immunotec Global PLC (OXFD) Director Richard A. Sandberg Sells 3,000 Shares
www.americanbankingnews.com - November 2 at 6:24 PM
Oxford Immunotec Global PLC (OXFD) Given a $21.00 Price Target by BTIG Research AnalystsOxford Immunotec Global PLC (OXFD) Given a $21.00 Price Target by BTIG Research Analysts
www.americanbankingnews.com - November 1 at 1:22 PM
Edited Transcript of OXFD earnings conference call or presentation 31-Oct-17 12:00pm GMTEdited Transcript of OXFD earnings conference call or presentation 31-Oct-17 12:00pm GMT
finance.yahoo.com - November 1 at 7:23 AM
ValuEngine Downgrades Oxford Immunotec Global PLC (OXFD) to SellValuEngine Downgrades Oxford Immunotec Global PLC (OXFD) to Sell
www.americanbankingnews.com - October 31 at 10:34 PM
Oxford Immunotec Global PLC (OXFD) Releases  Earnings Results, Misses Estimates By $0.25 EPSOxford Immunotec Global PLC (OXFD) Releases Earnings Results, Misses Estimates By $0.25 EPS
www.americanbankingnews.com - October 31 at 4:56 PM
Oxford Immunotec Global PLC (OXFD) PT Lowered to $19.00 at Piper Jaffray CompaniesOxford Immunotec Global PLC (OXFD) PT Lowered to $19.00 at Piper Jaffray Companies
www.americanbankingnews.com - October 31 at 11:54 AM
Oxford Immunotec Global PLC to Host Earnings CallOxford Immunotec Global PLC to Host Earnings Call
finance.yahoo.com - October 31 at 7:35 AM
Oxford Immunotec Reports Third Quarter 2017 Financial ResultsOxford Immunotec Reports Third Quarter 2017 Financial Results
finance.yahoo.com - October 31 at 7:35 AM
Oxford Immunotec Global PLC (OXFD) Expected to Post Quarterly Sales of $30.11 MillionOxford Immunotec Global PLC (OXFD) Expected to Post Quarterly Sales of $30.11 Million
www.americanbankingnews.com - October 25 at 6:20 PM
Oxford Immunotec Global PLC (OXFD) Set to Announce Quarterly Earnings on TuesdayOxford Immunotec Global PLC (OXFD) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 24 at 8:17 AM
Oxford Immunotec Global Plc – Value Analysis (NASDAQ:OXFD) : October 23, 2017Oxford Immunotec Global Plc – Value Analysis (NASDAQ:OXFD) : October 23, 2017
finance.yahoo.com - October 24 at 8:15 AM
Oxford Immunotec Global Plc breached its 50 day moving average in a Bearish Manner : OXFD-US : October 20, 2017Oxford Immunotec Global Plc breached its 50 day moving average in a Bearish Manner : OXFD-US : October 20, 2017
finance.yahoo.com - October 21 at 7:49 AM
Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31,Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31,
www.nasdaq.com - October 17 at 3:48 PM
Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31, 2017Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31, 2017
finance.yahoo.com - October 17 at 3:48 PM
Oxford Immunotec Global PLC (OXFD) Given Average Rating of "Hold" by AnalystsOxford Immunotec Global PLC (OXFD) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - October 17 at 2:52 AM
Oxford Immunotec Global PLC (OXFD) Upgraded to "Hold" at Zacks Investment ResearchOxford Immunotec Global PLC (OXFD) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 8 at 9:56 PM
 Analysts Anticipate Oxford Immunotec Global PLC (OXFD) Will Announce Quarterly Sales of $30.11 Million Analysts Anticipate Oxford Immunotec Global PLC (OXFD) Will Announce Quarterly Sales of $30.11 Million
www.americanbankingnews.com - October 6 at 6:44 AM

SEC Filings

Oxford Immunotec Global (NASDAQ:OXFD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Oxford Immunotec Global (NASDAQ:OXFD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Oxford Immunotec Global (NASDAQ OXFD) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.